---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-074712"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:59:22.793087+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports Q2 net loss $61.7M; cash $786.5M; aleniglipron data on track for year-end 2025

## Summary
- Net loss $61.7M vs $26.0M YoY; R&D expenses $54.7M (up from $22.1M) due to advancing GLP-1 program.
- Cash, equivalents, and short-term investments $786.5M; expected to fund operations through at least 2027.
- Topline data from aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts.
- Three new aleniglipron studies initiated: maintenance switching, body composition, T2DM, with enrollment Q3/Q4 2025.
- ACCG-2671 (oral amylin) Phase 1 initiation planned by year-end 2025; preclinical data presented.

## SEC filing metadata
- accession: 0001104659-25-074712
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465925074712/0001104659-25-074712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465925074712/tm2522431d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-074712
- JSON: https://secwatch.observer/filing/0001104659-25-074712.json
- Plain text: https://secwatch.observer/filing/0001104659-25-074712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.